Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure.
- 1 October 1983
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 68 (4), 803-812
- https://doi.org/10.1161/01.cir.68.4.803
Abstract
To determine the relationship between the early and late hemodynamic effects of captopril in patients with severe heart failure, we performed serial right heart catheterizations in 51 such patients who were treated with the drug for 2 to 8 weeks. Four hemodynamic patterns of response were observed. Nine patients had minimal responses initially (type I); six failed to improve during long-term treatment, but three showed delayed hemodynamic benefits. Twenty-eight patients had initial beneficial drug effects that were sustained after 48 hr and after 2 to 8 weeks (type II). In seven patients, first doses of captopril produced marked beneficial responses, but these became rapidly attenuated after 48 hr; nevertheless, continued therapy for 2 to 8 weeks was accompanied by spontaneous restoration of the hemodynamic effects of first doses of the drug, i.e., triphasic response (type III). In the remaining seven patients, attenuation of initial response was not reversed by prolonged captopril therapy; hemodynamic variables after 2 to 8 weeks had returned to their pretreatment values, i.e., drug tolerance (type IV). Plasma renin activity was lower in patients with minimal responses (0.6 +/- 0.2 ng/ml/hr) and was higher in patients with triphasic responses (9.4 +/- 2.5 ng/ml/hr) than in patients with types II and IV response patterns (4.4 +/- 0.7 and 2.8 +/- 0.5 ng/ml/hr, respectively; both p less than .05). Although first-dose effects of captopril are frequently sustained, the occurrence of delayed, attenuated, and triphasic responses indicates that a complex and variable relationship may exist between the early and late hemodynamic effects of vasodilator drugs in patients with severe heart failure.This publication has 38 references indexed in Scilit:
- Hydralazine in the long-term treatment of chronic heart failure: Lack of difference from placeboAmerican Heart Journal, 1982
- Hemodynamic Characterization of Tolerance to Long-Term Hydralazine Therapy in Severe Chronic Heart FailureNew England Journal of Medicine, 1982
- Decreased Lymphocyte Beta-Adrenergic-Receptor Density in Patients with Heart Failure and Tolerance to the Beta-Adrenergic Agonist PirbuterolNew England Journal of Medicine, 1981
- Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failureThe American Journal of Cardiology, 1981
- Importance of Left Ventricular Chamber Size in Determining the Response to Hydralazine in Severe Chronic Heart FailureNew England Journal of Medicine, 1980
- Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1980
- Rebound Hemodynamic Events after the Abrupt Withdrawal of Nitroprusside in Patients with Severe Chronic Heart FailureNew England Journal of Medicine, 1979
- Treatment of Chronic Congestive Heart Failure with Captopril, an Oral Inhibitor of Angiotensin-Converting EnzymeNew England Journal of Medicine, 1979
- Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.Hypertension, 1979
- Beta adrenergic blockade in hypertension: Practical and theoretical implications of long-term hemodynamic variationsThe American Journal of Cardiology, 1972